Verona Pharma (VRP)

 

VRP Share PerformanceMore

52 week high5.2450 15/03/16
52 week low2.1700 19/01/16
52 week change 0.1250 (3.88%)
4 week volume21,795,532 14/11/16

Media for (VRP)

Presenter: Jan-Anders Karlsson
27/07/2014

Technical Insight

Login or Register to access technical insights.

Latest NewsMore

Verona Pharma plans US public offering

Verona Pharma announces that it plans to conduct a registered initial public offering in the US. The number of shares an...

Registered Initial Public Offering in the US

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF REGULATION (EU) NO 596/2014 Verona Pharma Plans to Conduct Registered Initial Public Offering in the U.S. November 23, 2016, Cardiff ? Verona Pharma plc (AIM: VRP) today announced that it plans to conduct a registered initial public offering in th...

Exercise of options

RNS Number: 6784N Verona Pharma PLC 28 October 2016 Verona Pharma plc ("Verona Pharma" or the "Company") Exercise of Options The Company announces that it has issued 166,667 new ordinary shares in the capital of the Company (the "New Shares") following an exercise of share options by an employee. Application has been made to the London Stock E...

Second Venture and Innovation Award from the CF Trust

Verona Pharma plc ("Verona Pharma" or the "Company") Verona Pharma receives second Venture and Innovation Award from the Cystic Fibrosis Trust Supports first clinical study in patients to explore potential for RPL554 as a novel treatment for cystic fibrosis New data from pre - clinical studies to be presented at Annual North American Cystic Fibrosis Conf...

Notice of Cancellation of Trading on Xetra

Verona Pharma plc ("Verona Pharma" or the "Company") Notice of Cancellation of Trading on Xetra 19 October 2016, Cardiff ? Verona Pharma plc (AIM: VRP.L), the drug development company focused on first-in-class medicines to treat respiratory diseases, announces that it has applied to cancel its secondary trading listing on Xetra, a platform of the Frankfurt S...

Exercise of options

RNS Number: 0739L Verona Pharma PLC 28 September 2016 Verona Pharma plc ("Verona Pharma" or the "Company") Exercise of Options The Company announces that it has issued 166,667 new ordinary shares in the capital of the Company (the "New Shares") following an exercise of share options by an employee. Application has been made to the London Stock...

Appointment of CFO

Verona Pharma plc ("Verona Pharma" or the "Company") Appointment of CFO 26 September 2016, Cardiff ? Verona Pharma plc (AIM: VRP.L), the drug development company focused on first-in-class medicines to treat respiratory diseases, announces the appointment of Piers John Morgan as Chief Financial Officer with effect from 26 September 2016. Mr Morgan...

Half-year Report

Verona Pharma plc ("Verona Pharma" or the "Company") Interim results for the six months ended 30 June 2016 Significant clinical progress and strong balance sheet bodes well for future of RPL554 13 September 2016, Cardiff ? Verona Pharma plc (AIM: VRP.L), the drug development company focused on first-in-class medicines to treat respiratory diseases, today a...

Fundamental DataMore

EPS-0.73
Dividend yield0 %

Equity Research (VRP)

edison investment research
Verona Pharma plc
26/07/2016
Verona’s £44.7m gross raise removes funding uncertainty, allowing the company to focus on the clinical progress of its respiratory asset RPL554, a dual PDE3/PDE4 inhibitor. RPL554 is in development...
hardman & co
Verona Pharma plc
20/06/2016
VRP is developing first-in-class drugs to treat unmet medical needs in respiratory disease. Over the last two years’ VRP has reported positive outcomes from a five stage Phase I/IIa programme which...
hardman & co
Verona Pharma plc
16/03/2016
VRP is developing first-in-class drugs that treat unmet medical needs in respiratory disease. RPL554 is being fast-tracked to commercialisation by focusing on a $3.2bn market segment poorly serviced...

Latest discussion posts More

  • Re: ERS 2016

    congress highlights here http://www.respiratoryxchange.com/sites/default/files/documents/ERS2016_COPD_CongressReport_200916.pdf bit of a read for the weekend p55 ...
    10-Dec-2016
    mol42
  • Raptor66

    Hi Raptor, Thanks for that article comparing COPD to Asthma. I asked the question because my older brother suffered dreadfully with Chronic Asthma as a child and into his ...
    6-Dec-2016
    lawrence77
  • Re: COPD Competition ??

    http://www.everydayhealth.com/hs/healthier-living-with-copd/copd-and-asthma/
    2-Dec-2016
    raptor66

Users' HoldingsMore

Users who hold Verona Pharma also hold..
LLOYDS GRP.21%
GULF KEYSTONE12%
RENEURON11%
RANGE RES.10%
BP9%

Codes & Symbols

ISINGB00B06GSH43
SymbolsVRP, LSE:VRP, VRP.L, VRP:LN, LON:VRP, XLON:VRP